AQR Capital Management LLC Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

AQR Capital Management LLC acquired a new position in Verve Therapeutics, Inc. (NASDAQ:VERV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 95,571 shares of the company’s stock, valued at approximately $466,000. AQR Capital Management LLC owned about 0.11% of Verve Therapeutics as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Nomura Holdings Inc. lifted its stake in shares of Verve Therapeutics by 5.0% during the 4th quarter. Nomura Holdings Inc. now owns 19,076 shares of the company’s stock valued at $266,000 after buying an additional 900 shares in the last quarter. Cornercap Investment Counsel Inc. boosted its stake in shares of Verve Therapeutics by 13.5% during the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock valued at $73,000 after purchasing an additional 1,778 shares in the last quarter. Arizona State Retirement System lifted its position in Verve Therapeutics by 14.1% during the second quarter. Arizona State Retirement System now owns 16,386 shares of the company’s stock valued at $80,000 after acquiring an additional 2,019 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Verve Therapeutics in the fourth quarter worth $29,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Verve Therapeutics in the fourth quarter worth $30,000. Institutional investors own 97.11% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on VERV. Canaccord Genuity Group decreased their price target on shares of Verve Therapeutics from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $25.00 to $20.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Verve Therapeutics in a research report on Monday, August 12th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $26.00.

Verve Therapeutics Stock Up 7.7 %

Shares of NASDAQ VERV opened at $5.03 on Tuesday. The stock’s 50 day moving average price is $5.22 and its two-hundred day moving average price is $5.99. Verve Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $20.12. The stock has a market capitalization of $422.34 million, a P/E ratio of -1.75 and a beta of 1.80.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.09. Verve Therapeutics had a negative return on equity of 35.20% and a negative net margin of 933.08%. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $2.40 million. During the same period last year, the company earned ($0.87) earnings per share. Verve Therapeutics’s quarterly revenue was up 219.0% compared to the same quarter last year. On average, analysts anticipate that Verve Therapeutics, Inc. will post -2.65 EPS for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.